No Data
Guangzhou Baiyunshan Pharmaceutical Unit Gets Additions to Drug Production License
With declining performance and senior executives falling from power, why can't baiyunshan (00874) rise up relying on domestic "Viagra"?
Whether it is the early involvement in the "network removal" incident, where certain pharmaceutical products in provinces like shanxi, anhui, guizhou, shandong were stripped of their online procurement qualifications; or the failure of its subsidiary Guangzhou Pharmaceuticals' IPO, or the turmoil in senior management and decline in performance since 2024, all indicate that baiyunshan ph's development may not be smooth.
Baiyunshan (00874.HK) subsidiary pharmaceutical production license change.
November 18th, Baiyunshan (00874.HK) announced that recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company")'s wholly-owned subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Mingxing Pharmaceutical") received the "Pharmaceutical Production License" approved and issued by the Guangdong Provincial Pharmaceutical Supervision Administration, agreeing to add new production workshops, production lines, and production scopes for Mingxing Pharmaceutical, and passing the compliance inspection of pharmaceutical production quality management standards. Agreed that Mingxing Pharmaceutical is located at "99 Jianxu San Road, Baiyun District, Guangzhou City", with new production workshops "Manufacturing Department Six, Manufacturing Department Eight", and new
Hong Kong's Department of Health: To develop Hong Kong into a gateway for the internationalization of traditional Chinese medicine and Chinese herbal medicine.
Secretary for Food and Health of the Hong Kong Special Administrative Region, Dr. Constance Chan, stated that in order to promote the standardization and internationalization of traditional chinese medicine, Hong Kong aims to become a gateway for the internationalization of traditional chinese medicine.
Baiyunshan (00874.HK) was subjected to shareholding of 0.808 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 7th, 2024, baiyunshan ph (00874.HK) was shareholding by Norges Bank at an average price of HK$18.3615 per share on November 1, 2024, reducing 0.808 million shares, involving approximately HK$14.8361 million. After the shareholding, Norges Bank's latest number of shares held is 19.757 million shares, and the shareholding ratio decreased from 9.35% to 8.98%.
Baiyunshan Pharmaceutical (00874.HK) obtained a supplement application approval for pharmaceuticals at its branch.
Galunhui November 6th | Baiyunshan (00874.HK) announced that recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'the Company')- Baiyunshan Pharmaceutical Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'Baiyunshan Pharmaceutical Factory') received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration (referred to as 'NMPA'). Baiyunshan Pharmaceutical Factory obtained the Drug Supplementary Application Approval Notice for Citric Acid Sildenafil Tablets this time, enriching the variety of its pharmaceutical products, helping enhance the Company's competitiveness in the pharmaceutical market. Baiyunshan Pharmaceutical
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed DownNo Data
No Data
